- Kite Pharma (NASDAQ:KITE) is up a fraction premarket on light volume in response to the results from a National Cancer Institute (NCI)-led research study assessing a single dose of anti-CD19 CAR T-cell therapy in 22 patients with refractory/relapsed non-Hodgkin lymphoma (NHL). The data were just published in the Journal of Clinical Oncology.
- Objective response (OR) rate was 73% (n=16/22) and the complete response (CR) rate was 55% (n=12/22). In patients with aggressive B-cell NHL, OR and CR were 68% and 47%, respectively. Duration of responses ranged from more than seven months to more than 24 months, with 11 of 12 (92%) complete responders ongoing.
- Reversible grade 3 (severe) or grade 4 (life-threatening) neurotoxicity was observed in 55% (n=12/22) of treated patients.
- The results build on the successful Phase 3 ZUMA-1 trial of axicabtagene ciloleucel that showed 36% CR and extended survival.
- Previously: Kite's lead product candidate successful in late-stage blood cancer study (Feb. 28)